CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 105,293	$ 90,326
Accounts receivable, net	320,320	269,312
Inventories	229,377	195,019
Other current assets	124,622	124,982
Total current assets	779,612	679,639
Long-Term Assets:
Property and equipment, net	550,895	533,845
Operating lease right-of-use assets	82,407	80,607
Goodwill	235,426	239,724
Intangible assets, net	55,619	58,468
Other long-term assets	256,754	240,192
Total long-term assets	1,181,101	1,152,836
TOTAL ASSETS	1,960,713	1,832,475
Current Liabilities:
Accounts payable	73,903	72,172
Accrued liabilities	308,768	322,938
Line of credit	121,596	288,765
Current portion of deferred revenue	36,317	41,462
Total current liabilities	540,584	725,337
Long-Term Liabilities:
Deferred income tax liabilities	36,599	33,024
Long-term debt	899,562	698,910
Long-term deferred revenue, net of current portion	57,764	48,743
Long-term operating lease liabilities	68,597	67,472
Other long-term liabilities	84,207	81,164
Total long-term liabilities	1,146,729	929,313
Total liabilities	1,687,313	1,654,650
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 106,031 shares in 2020 and 105,711 shares in 2019; Outstanding: 85,049 shares in 2020 and 85,471 shares in 2019	10,603	10,571
Additional paid-in capital	1,247,456	1,213,517
Deferred stock units: Outstanding: 147 units in 2020 and 143 units in 2019	5,402	4,462
Retained earnings	1,854,586	1,595,648
Accumulated other comprehensive loss	(57,032)	(46,182)
Treasury stock, at cost: 20,981 shares in 2020 and 20,240 shares in 2019	(2,788,052)	(2,600,543)
Total IDEXX Laboratories, Inc. stockholders’ equity	272,963	177,473
Noncontrolling interest	437	352
Total stockholders’ equity	273,400	177,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,960,713	$ 1,832,475